Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories (NYSE:ABT), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Abbott Laboratories. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $240,592, and 3 are calls, amounting to $244,878.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $105.0 to $130.0 for Abbott Laboratories over the recent three months.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Abbott Laboratories's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's whale activity within a strike price range from $105.0 to $130.0 in the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
ABT | CALL | SWEEP | BULLISH | 11/15/24 | $8.8 | $8.65 | $8.8 | $105.00 | $160.1K | 382 | 182 |
ABT | PUT | TRADE | NEUTRAL | 08/16/24 | $19.1 | $18.6 | $18.87 | $125.00 | $94.3K | 3 | 50 |
ABT | CALL | SWEEP | BULLISH | 11/15/24 | $8.85 | $8.65 | $8.8 | $105.00 | $58.9K | 382 | 249 |
ABT | PUT | TRADE | BEARISH | 05/17/24 | $23.65 | $23.1 | $23.48 | $130.00 | $44.6K | 0 | 19 |
ABT | PUT | SWEEP | BULLISH | 05/17/24 | $1.05 | $1.02 | $1.02 | $106.00 | $38.2K | 218 | 679 |
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $129.5.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Abbott Laboratories, Benzinga Pro gives you real-time options trades alerts.
Posted In: ABT